The identification of cell-free fetal DNA circulating in maternal blood combined with technological developments, in particular next-generation sequencing, is enabling the development of safer prenatal diagnosis. While this technology has been widely applied as a highly sensitive screening test for aneuploidy, there has been relatively little clinical application for the diagnosis of monogenic disorders. In the UK, we have established non-invasive prenatal diagnosis (NIPD) as a clinical service for a range of inherited disorders. The results from NIPD do not require confirmation by invasive testing and are welcomed by patients and health professionals alike. Here, we describe the technical approaches used, current practice and outline recommendations for best practice when delivering an NIPD service from an accredited laboratory.
plasma is a mix of maternal and fetal cfDNA. When testing for monogenic disorders either because of a family history or because of suspicious ultrasound findings, analysis is targeted, and therefore, results obtained using NIPD do not require confirmation and are therefore diagnostic, circumventing the documented small risks associated with invasive testing. 2 This is in contrast to screening of cfDNA for aneuploidy where an abnormal result can reflect cell lines that are confined to the placenta (confined placental mosaicism) or are maternal in origin and so requires confirmation by invasive prenatal analysis of fetal genetic material. 3 Across the globe, in clinical practice, the use of cfDNA has been mainly focused on screening for aneuploidy, largely because of greater demand and commercial drive. 4 However, in the UK, NIPD for monogenic disorders has been offered on a research basis since 2006 and, for some indications, has formal National Health Service (NHS) approvals in place since 2011. 5 Establishing an accredited NIPD service is challenging, not least because in many cases, testing has to be provided on a bespoke, patient or disease-specific basis using methods that are labour intensive and not as readily scalable as screening for aneuploidy. There have been various technologies so far applied to NIPD; the requirements of a test will vary according to factors such as the inheritance pattern of the disorder, the detection level required, mutation type and equipment and expertise available. Here, we review the progress that has been made to date, the different technologies and their associated challenges, and also address factors such as validation, quality control, turnaround time and cost to show how it is possible to deliver a clinical NIPD service in accredited public sector laboratories.
TECHNICAL APPROACHES TO NIPD
The most straightforward scenario for NIPD is to detect the presence or absence of a mutation that is not present in the mother. Thus, initial approaches to NIPD focused on the identification of sequences inherited from the father, 6 such as Y chromosome markers to determine fetal sex 5 or RHD status, 7 and the detection of de novo mutations in pregnancies with fetal anomalies on ultrasound. 8, 9 Technologies include real-time PCR, targeted/ampliconbased next-generation sequencing (NGS), digital PCR (including droplet digital PCR), mini-sequencing, cSMART and COLD-PCR and all involve developing an assay for detection of a mutation that is not present in the maternal component of the cfDNA 6, 10 (Table 1) .
Real-time PCR
Rather than a specific disease causing mutation, some applications are based upon the detection of a generic fetal sequence common to a subset of pregnancies such as the presence of Y chromosome sequence in any male-bearing pregnancy for fetal sexing or the presence of the RHD gene to determine Rhesus D status. In these situations, real-time PCR assays have been used to measure the accumulation of targeted DNA sequences as the PCR reaction progresses. Using this approach, cffDNA analysis to detect Y chromosome material is now part of standard prenatal care for pregnancies at risk of severe sex-linked conditions in many parts of Europe and beyond. This allows avoidance of invasive testing in around 50% of pregnancies by triaging only pregnancies of the appropriate sex for invasive testing, for example malebearing pregnancies for Duchenne muscular dystrophy 5 or female pregnancies for congenital adrenal hyperplasia. 27 Two standardisation workshops were held followed by a pilot External Quality Assessment (EQA) scheme in 2010. Approval for delivery in the NHS was granted by the UK Genetic Testing Network in 2011 for three English laboratories.
PCR with restriction enzyme digest
Some of the first disease-specific NIPD tests to be delivered clinically utilised PCR with restriction enzyme digest (PCR-RED) to target mutations in the FGFR3 gene that are commonly associated with achondroplasia and thanatophoric dysplasia. 8, 9 PCR-RED uses restriction enzymes to cleave DNA at a specific sequence harbouring the mutation. While this is a rapid and relatively cheap method, it requires analysis of agarose gel electrophoresis images that can be subjective to interpret (Figure 1 ), has an inconclusive rate of around 8%, meaning that a report cannot be issued, and cannot be applied to all mutations. 8 However, where the result identifies or excludes a mutation, this has been found to be highly accurate in follow-up to pregnancy outcome studies. 11 In addition, this approach can only be used to detect one mutation at a time, which makes it impractical for use in pregnancies presenting with unexpected ultrasound findings where the mutation is not known, particularly when disease causing genes may be heterogeneous.
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Next-generation sequencing
The advent of NGS, and in particular desk-top sequencers, has allowed expansion of NIPD to include the development of targeted amplicon-based tests that encompass multiple known mutations in selected genes 10, 11, 14 and more complicated genetic analysis for diagnosis of recessive, 24 X-linked 25 and maternally inherited dominant conditions. This has been applied to mutations in the FGFR3 gene to enable simultaneous analysis of all 29 known disease-causing mutations including achondroplasia and thanatophoric dysplasia. 11 Compared with PCR-RED, NGS significantly improves coverage and sensitivity and has been used in routine clinical service since 2014. Extensive validation was undertaken prior to implementation with analysis of postnatal samples or confirmation of a normal outcome prior to implementation into clinical service. 11 The panel approach can also be used to aid prenatal diagnosis in recessive disorders where parents carry different mutations. Here, exclusion of the paternal allele indicates that the fetus will not be affected, while if it has been inherited, then an invasive test is required to determine inheritance of the high-risk maternal allele. This has been used in clinical practice, again after extensive clinical validation and confirmation of outcomes to confirm accuracy for cases where reports were issued, for the diagnosis of cystic fibrosis 14 and beta thalassaemia. 17 This approach is now in clinical use to develop bespoke testing on a family by family basis for a wide range of rare conditions that have either apparently arisen de novo in a previous pregnancy and present a small risk of recurrence due to parental germline mosaicism, or to exclude inheritance of the paternal mutant allele in autosomal dominant or recessive conditions. This testing can be achieved with turnaround times of 5 days. 10 Bioinformatic analysis of NGS data has facilitated the implementation of extensive internal quality checks, for example to remove poor quality sequence reads and to monitor for inter-run contamination.
NIPD FOR AUTOSOMAL RECESSIVE AND X-LINKED DISORDERS
Definitive NIPD for autosomal recessive and X-linked conditions is technically demanding and requires determination of the inheritance of the maternal allele. This is complicated because of the high levels of circulating maternal alleles and thus requires assessment of the relative quantities of mutant and wild-type alleles. To achieve this level of sensitivity, techniques such as relative mutation dosage (RMD) 18 and relative haplotype dosage (RHDO) 23 have been developed 23 using NGS and digital PCR 18, 28 (Table 1) .
Relative mutation dosage
This approach measures the proportion of wild-type and mutant alleles in cfDNA ( Figure 2 ). 18 For a homozygous affected
fetus, RMD will demonstrate increased levels of the mutant allele, whereas if mother and fetus share the same genotype allelic, balance is predicted. Where the fetus is homozygous wild-type, RMD will indicate reduced levels of the mutant allele and an increase in the relative wild-type allele contribution. Digital PCR facilitates accurate measurement of RMD in maternal plasma samples, and droplet digital PCR has been used to provide NIPD for maternally inherited disease. 19 The proportion of cffDNA in plasma was established by examining those alleles that were different and calculating their ratios of balance or imbalance. Where there was an apparent allelic balance between maternal and fetal genotypes, the presence of fetal DNA was confirmed by a separate method, namely digital PCR, to detect Y chromosome markers in male-bearing pregnancies and to identify informative polymorphic markers in female-bearing pregnancies.
Relative haplotype dosage analysis
Relative haplotype dosage can be applied for NIPD of single gene disorders and goes beyond paternally inherited mutations to combine relative mutation dosage with linkage analysis. By analysing regions of single-nucleotide polymorphisms (SNPs) in a haplotype linked to the disease gene rather than a specific mutation, this highly effective approach can be used to detect more complex genetic mutations. This is particularly advantageous for genes with pseudogenes, larger gene deletions and pathogenic variants located within repetitive elements. 22 The RHDO approach determines the allelic ratios between two haplotypes in maternal plasma. Lam and colleagues 23 demonstrated that deducing fetal inheritance using RHDO is superior to the RMD approach in that it includes allele counts within a haplotype, thus increasing the statistical power of the method. Elucidating the fetal haplotype is accomplished by using particular SNPs to deduce maternal and paternal inheritance dependent on the inheritance pattern of the disorder.
Relative haplotype dosage analysis is used to calculate the allelic ratios in the maternal plasma for haplotype blocks. It follows then that the greater the number of SNPs included in the analysis, the higher the statistical power. Figure 3 is an illustration of deduction of the fetal haplotype using RHDO. By identifying the maternal and paternal haplotypes linked to the mutation, RHDO allows for detection of haplotype (normal or mutant) inherited by the fetus.
Statistical significance in RHDO analyses is resolved using a sequential probability ratio test (SPRT), and statistical strength is derived sequentially building up of results from ratios of Hap1 and Hap2 (classifications). The SPRT statistical test is more robust as it is performed in both directions 5 0 to 3 0 and 3 0 to 5 0 allowing recombination points to be accurately identified by using bidirectional SPRT classifications to predict crossing over.
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Relative haplotype dosage has been employed for NIPD of the allelic X-linked disorders Duchenne muscular dystrophy and Becker muscular dystrophy 25 and also the autosomal recessive conditions congenital adrenal hyperplasia, 22 spinal muscular atrophy 24 and cystic fibrosis. 10 The primary advantage of RHDO is that analysis is not restricted by mutation type. However, there are several limitations of RHDO analysis. One is in the analysis of consanguineous pregnancies where haplotypes that are identical by descent may result in a lack of informative SNPs. The second is in the need for DNA from an affected family member to allow for haplotype phasing. More recently, a method has been developed that uses 10× Genomics technology and short-read sequencing to build haplotype resolved sequences and enable phasing of mutations in parental samples. 29 This would potentially negate the requirement for DNA from an affected family member and so would make RHDO analysis accessible to more couples. At the time of writing, however, the cost of this technology is prohibitive to clinical application.
CHALLENGES IN ESTABLISHING AN NIPD SERVICE
There are many challenges in developing a clinical service based on NIPD. These include having sufficient samples to develop and validate the assays, particularly when considering the rarity of some of these conditions, sample handling, confirming the presence of cfDNA and measuring the fetal fraction. Developing a quality assurance scheme is also essential for monitoring and accreditation purposes. In the UK, there are two laboratories that deliver an accredited NIPD service; both received grant funding, the RAPID programme from the National Institute for Health Research (NIHR RP-PG-0707-10107) and the NIPSIGEN project funded by the Health Innovation Challenge Fund (Wellcome Trust and Department of Health). This allowed the collection of significant numbers of plasma samples from at risk pregnancies as well as funding the initial development work.
Fetal fraction
Cell-free DNA in maternal plasma is derived from apoptosis of both maternal cells and placental cytotrophoblast cells. 30 The relative quantities are highly variable both between and within pregnancies, although the proportion of cfDNA from the placenta is usually around 5-10% and generally increases as the pregnancy progresses. Factors influencing this variability include gestation, placental size, maternal smoking, maternal body mass index and pre-eclampsia. 31 Given the unpredictable nature of these factors, it is important to have a measure of fetal fraction as a quality control parameter for any NIPD assay. This is particularly important where the assay indicates a negative result, that is that the fetus has not inherited a mutation, as this could be a null result caused by a fetal fraction below the detection level of the assay. Fetal fraction can be measured by a number of different methods based on fragment size, sequence context, differences in methylation, presence of Y chromosome for male fetuses and informative SNPs showing inheritance of a paternal allele (reviewed by Peng and Jiang 32 ). Fetal fraction is notoriously difficult to measure accurately, particularly at low levels, and there is variability between different methods. In general, it is better to use an NIPD testing method, which also measures the fetal fraction, to give an internal quality control (IQC) parameter. For example, this is possible for SNP-based methods of NIPD such as RHDO, where the panel of SNPs analysed also includes those for fetal fraction as a key parameter in the statistical analysis.
Sample handling and DNA extraction
As described previously, the cfDNA in maternal plasma is a mix of maternal and fetal DNA. When collected into standard EDTA tubes, the maternal white blood cells will continue to lyse, thereby increasing the relative proportion of maternal cfDNA. Prior to implementation of clinical tests for NIPD, we undertook extensive evaluation of sample handling and time to processing in order to optimise the yield of cffDNA from maternal blood plasma. 33 These studies clearly showed that plasma must be separated from whole blood as soon as possible after blood draw to maintain the maximum proportion of fetal DNA. This is particularly important for NIPD where relative mutation or haplotype levels are being measured rather than the absolute presence or absence of a mutation. If this is not practical, then cell stabilising tubes should be used to minimise maternal cell haemolysis, thereby maximising fetal fraction. Manual and automated DNA extraction methodologies have also been subject to lengthy evaluation and validation to ensure that the, typically shorter, fetal DNA fragments are optimally represented in the final extract. The adopted extraction approach is largely dependent on throughput requirements with both automated and manual methods, once optimised, yielding DNA extracts of comparable quality.
In clinical service, it is essential to monitor the sample type and time to processing; clear guidance must be provided to Figure 3 An illustrative example of fetal inheritance. By constructing parental and proband haplotypes, linking the mutation to the haplotype in the proband and then calculating the relative haplotype dosage. In this example, the fetus has inherited the mutated haplotype from the father and normal haplotype from the mother (grey shading). The resulting genotype is unaffected carrier. M,maternal; Mut, haplotype linked to the mutation; Norm, haplotype linked to the normal allele; P, paternal; RHDO, relative haplotype dosage. Adapted from New et al.
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referrers on sample handling and transport to optimise downstream DNA extraction and testing.
Quality control
As with the introduction of any new test into clinical service, it is important to ensure the accuracy and reliability of the NIPD test. IQC must be performed during the validation and clinical application each time a test is carried out. For NIPD, IQC parameters should include a minimum standard for read depth and measurement of fetal fraction integral to the assay. If fetal fraction cannot be calculated, a repeat test should be offered at a later gestation. In delivering a clinical service, IQC standards must be met at all times to provide confidence in accurately interpreting the results obtained. However, to meet International Standards for medical laboratories, for example ISO 15189:2012 (https://www.ukas.com/services/ accreditation-services/medical-laboratory-accreditation-iso-15189/), participation in an external exercise that demonstrates the quality of the service is required. Many tests are assured through participation in EQA schemes, often known as proficiency testing; however, the bespoke nature of NIPD means that it is challenging to design and deliver a cost-effective assessment for every type of case. Sample swap exercises between laboratories providing NIPD are one way of addressing this need, but the lack of external facilitation is problematic; if suboptimal performance is detected then there are no mechanisms in place to deal with the issues. EQA schemes are in development to assess different testing strategies outlined previously, using a modular approach. The DNA testing and reporting is assessed through the provision of family samples with an appropriate clinical case scenario. Participation in combination with plasma-based NIPT schemes will ensure that the end-to-end process is quality assured for the laboratory.
Recommendations/best practice
It is advisable when developing a laboratory NIPD service to have clinical input and to accept referrals primarily through a Clinical Genetics or specialist Fetal Medicine service. Referrals are generally relatively rare, and laboratories should work in conjunction with specialist counsellors who will provide patients with appropriate information, obtain consent and ensure access to relevant DNA samples from family members in line with standard guidelines in place for any prenatal diagnostic test. 34 Prior to offering NIPD, the laboratory requires access to clinical information such as pedigree structure and copies of previous reports and also to familial mutation control samples. Dependent on the assay, there may be a requirement for validation using familial controls, and in some cases, this is necessary prior to a pregnancy. In some cases, it may not be possible to develop an assay for technical reasons. This may be due to the characteristics of the mutation being detected and technical problems such as artefacts or sequence context. It may alternatively be specific to the couple seeking testing, for example in some cases, the presence of low level mosaicism for the mutation in maternal blood. To date, in the UK, in general, NIPD is only offered for a disorder or mutation for which invasive testing would be considered appropriate, for example a pathogenic or likely pathogenic variant according to the American College of Medical Genetics and Genomics guidelines. 35 
Cost
The cost of NIPD delivery in the public sector has proved to be a key factor with demand likely to rise due to increased test uptake, as parents use NIPD for information about their fetus to gain reassurance of normality early in pregnancy. The cost may be mitigated using NGS to deliver panel testing covering a range of mutations and also by multiplexing a number of cases. Increased throughput will also reduce costs but may require concentration of testing in selected laboratories. By performing two to three cases per week in our laboratory, NIPD for paternal or de novo mutation detection or exclusion is cheaper than invasive testing. Bespoke design and validation of family-specific NIPD assays increases costs, as does definitive diagnosis in recessive conditions using RHDO. These are in the region of £500-£900 more expensive.
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REQUIREMENTS FOR IMPLEMENTING MOLECULAR TESTS
Prior to the introduction of a new molecular genetic test in the UK, a thorough evaluation in the form of a gene dossier is required. Submitted by the provider laboratory, dossiers are assessed against a range of parameters prior to approval for commissioning within the NHS. These requirements are summarised in Box 1 and form a helpful framework for standardisation. 
STAKEHOLDER VIEWS
A number of studies have shown that women and health professionals are very positive about NIPD as it reduces the need for invasive procedure, is highly accurate and can be conducted earlier in pregnancy. 14, 37, 38 For women with a family history of a single-gene disorder, NIPD reduced the Delivering an accredited non-invasive prenatal diagnosis service period of stress resulting from not knowing whether the fetus was affected and in an unaffected fetus enabled fetal-maternal bonding to take place. Where there was a low recurrence risk following a previous affected pregnancy, early reassurance was identified as the main benefit. The key psychological benefit was providing parents with information, so they could prepare themselves for the birth and have time to gain understanding of the condition. Participants in one study also thought that uptake of prenatal testing was likely to increase as women who had previously declined invasive testing expressed interest in using a non-invasive testing that was safe and could be conducted early. 14 However, there are those who argue that, despite the psychological benefits, cost mitigates against offering NIPD to families at low risk of recurrence because of germline mosaicism, 39 but they do not take into account of the relief from anxiety that early reassurance can offer, or the fact that some will opt for invasive testing if NIPD is not available. While the clinical and psychological benefits of NIPD are clear, a number of ethical issues associated with the technology have been identified. 40 Firstly, there is the potential for routinisation of testing if insufficient consideration is given to the decision with the associated undermining of informed consent. In addition, use of NIPD for 'information only' (with no intention to terminate) where the test does not change pregnancy management has resource implications. Concern has also been raised that NIPD will lead to increased societal pressure to test and terminate an affected pregnancy. 37 In addition, there is the possibility that if NIPD is used to test for an autosomal recessive condition for which both parents need to be carriers of the mutation for the fetus to be affected, the paternal carrier status may be revealed even if he had declined carrier testing. One study showed that mothers should be able to request such tests but that fathers who declined carrier testing should be made aware that NIPD may reveal their status. 41 While these concerns are not necessarily new as they equally apply to invasive testing, the ease with which NIPD can be conducted and the lack of any associated risk may alter the choices presented to women and families with a corresponding change to the moral nature of prenatal diagnosis.
CONCLUSIONS
The nature and scope of prenatal diagnosis is changing rapidly, and NIPD is gradually becoming available for many inherited conditions. Development of an accredited service is possible, but it raises challenges and, for many conditions, is expensive and labour intensive. Development of recommendations and guidelines for laboratory standards is required for integration into routine clinical practice, along with quality assurance and training procedures for health professionals. Although NIPD test repertoire and availability is improving, clear and accessible patient and healthcare professional information resources are required to ensure equitable access for families and maintenance of informed parental decisionmaking to address some of the concerns raised by key stakeholders. At present, as with general genetic testing, NIPD is only available in the NHS to families with a relevant history and who are at risk of an affected pregnancy. While prenatal population screening for monogenic disorders is not generally available in the public sector in the UK, private screening is starting to become available, with some companies in the United States already offering screening by NIPD for new dominant mutations. The potential availability of screening for the 'worried well' brings further ethical challenges and potential downstream impact on healthcare services.
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WHAT'S ALREADY KNOWN ABOUT THIS TOPIC?
• Identification of cell-free fetal DNA in the maternal circulation has enabled the development of safer prenatal diagnosis, reducing the number of invasive tests required.
• To date, in clinical practice, this technology largely has been used as a highly sensitive screening test for aneuploidy.
WHAT DOES THIS STUDY ADD?
• Development of an accredited laboratory service for non-invasive prenatal diagnosis of monogenic conditions is possible, allowing families at risk of inherited disorders access to safe, early prenatal diagnosis, but it raises challenges and, for many conditions, is expensive and labour intensive.
• Development of recommendations and guidelines for laboratory standards is required for integration into routine clinical practice, along with quality assurance and training procedures for health professionals.
• As the use of this technology expands, ethical issues will arise with regard to what tests should be offered and to whom. Further exploration of these issues is required with the development of guidelines for use.
